Complement mutations in diacylglycerol kinase-ε-associated atypical hemolytic uremic syndrome.

ABSTRACT:

Background and objectives

Atypical hemolytic uremic syndrome is characterized by vascular endothelial damage caused by complement dysregulation. Consistently, complement inhibition therapies are highly effective in most patients with atypical hemolytic uremic syndrome. Recently, it was shown that a significant percentage of patients with early-onset atypical hemolytic uremic syndrome carry mutations in diacylglycerol kinase-ε, an intracellular protein with no obvious role in complement. These data support an alternative, complement-independent mechanism leading to thrombotic microangiopathy that has implications for treatment of early-onset atypical hemolytic uremic syndrome. To get additional insights into this new form of atypical hemolytic uremic syndrome, the diacylglycerol kin

SUBMITTER: Sanchez Chinchilla D 

PROVIDER: S-EPMC4152807 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature